IL4 and relapsing-remitting multiple sclerosis: Notably, LXR activation did alter function in CD4 + T-cells from RRMS patients demonstrated by significantly reduced intracellular IL-17A expression, reduced proliferation (Ki67), and increased IL-4 production in (Fig. 5C and D), as we observed previously in HCs [8], although interferon-γ production was unaffected.